Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | CFD | P00746 | 16/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718308 | 0.83 | P2RX7 (0.36) | GRIA1CACNG8RORCCFDPTGDR2 | |
| SCHEMBL4720108 | 0.83 | PTGDR2 (0.37) | GRIA1CACNG8RORCPTGDR2 | |
| SCHEMBL4762925 | 0.73 | HTR6 (0.42) | GRIA1CACNG8RORC | |
| SCHEMBL4717899 | 0.71 | TAAR1 (0.49) | — | |
| SCHEMBL11132912 | 0.70 | MEN1 (0.39) | — | |
| SCHEMBL22126531 | 0.70 | MCL1 (0.40) | RORCPTGDR2NOTUM | |
| SCHEMBL28977326 | 0.67 | NOTUM (0.47) | PTGDR2NOTUM | |
| SCHEMBL3562734 | 0.65 | L3MBTL1 (0.45) | — | |
| SCHEMBL26621992 | 0.65 | KDM4E (0.47) | GRIA1CACNG8RORC | |
| SCHEMBL21585199 | 0.64 | RORC (0.48) | GRIA1CACNG8RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660484-B1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPHA-1 ADRENERGIC AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1660484-A1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPHA-1 ADRENERGIC AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-6979696-B2 | Method for detecting a gram-negative bacterial autoinducer molecule | ROCHE PALO ALTO LLC (US) | 2005-12-27 | — | — | US | disclosed |
| WO-2004099189-A1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPH-1 ADRENERGIC AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224973-A1 | Substituted indoles as alpha-1 agonists | ROCHE PALO ALTO LLC | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224973-A1 | Substituted indoles as alpha-1 agonists | ADRA1A, ADRB1, ADRA1D | GRIA1 202/4885CACNG8 999/4885RORC 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.